Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

360
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
360
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

758
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
758
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

633
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
633
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

586
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
586
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

640
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
640
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxychloroquine for recurrent pericarditis.

European journal of internal medicine·2026
Same author

Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases.

European journal of heart failure·2026
Same author

Perspective on Corticosteroid Use and Interleukin-1 Inhibition With Anakinra in Pericarditis During Pregnancy.

JACC. Advances·2026
Same author

Hydroxychloroquine for recurrent pericarditis: A multicentre observational study.

European journal of internal medicine·2026
Same author

ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling.

Open heart·2026
Same author

[2025 ESC Guidelines for the management of myocarditis and pericarditis].

Giornale italiano di cardiologia (2006)·2025

Related Experiment Video

Updated: May 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

Colchicine for recurrent pericarditis (CORP): a randomized trial.

Massimo Imazio1, Antonio Brucato, Roberto Cemin

  • 1Maria Vittoria Hospital and Ospedale degli Infermi, Torino, Ospedali Riuniti, Bergamo, San Maurizio Regional Hospital, Bolzano, Italy. massimo_imazio@yahoo.it

Annals of Internal Medicine
|August 30, 2011
PubMed
Summary
This summary is machine-generated.

Colchicine significantly reduced recurrent pericarditis rates by 56% compared to placebo over 18 months. This study confirms colchicine as a safe and effective option for preventing pericarditis recurrence.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K

Related Experiment Videos

Last Updated: May 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pharmacology

Background:

  • Recurrent pericarditis affects 10-50% of patients, representing a common complication.
  • Secondary prevention strategies are crucial for managing this condition.

Purpose of the Study:

  • To evaluate the efficacy and safety of colchicine for secondary prevention in patients experiencing recurrent pericarditis.
  • To assess colchicine's impact on recurrence rates and associated symptoms.

Main Methods:

  • A prospective, randomized, double-blind, placebo-controlled multicenter trial involving 120 patients with a first recurrence of pericarditis.
  • Patients received conventional treatment plus either placebo or colchicine (1.0-2.0 mg loading dose, then 0.5-1.0 mg/d) for 6 months.
  • Primary endpoint: recurrence rate at 18 months; secondary endpoints included symptom persistence, remission rates, and hospitalizations.

Main Results:

  • Colchicine demonstrated a 56% relative risk reduction in recurrence rates at 18 months (24% vs. 55% in placebo group).
  • Colchicine significantly reduced symptom persistence at 72 hours and the mean number of recurrences.
  • The drug also increased remission rates at 1 week and prolonged time to subsequent recurrence, with similar side effect profiles to placebo.

Conclusions:

  • Colchicine is a safe and effective agent for the secondary prevention of recurrent pericarditis.
  • The findings support the use of colchicine in clinical practice to reduce pericarditis recurrence.